Table 3. Antipsychotic monotherapy and polypharmacy according diagnosis (n = 1116).
| Diagnosis | Patient with specific diagnostic N (%) | Antipsychotic use | Antipsychotic monotherapy | Antipsychotic polypharmacy | |
|---|---|---|---|---|---|
| One diagnosis | F0-F09 | 44 (1.0%) | 26 (2.3%) | 23 (2.8%) | 3 (1%) |
| F10-F19 | 111 (2.6%) | 26 (2.3%) | 24 (2.9%) | 2 (0.7%) | |
| F20-F29 | 476 (11.0%) | 462 (41.4%) | 305 (36.8%) | 157 (54.7%) | |
| F30-F39 | 966 (22.2%) | 268 (24%) | 204 (24.6%) | 64 (22.2%) | |
| F40-F49 | 1630 (37.5%) | 82 (7.3%) | 78 (9.4%) | 4 (1.4%) | |
| F50-F59 | 101 (2.3%) | 9 (0.8%) | 9 (1.1%) | 0 (0%) | |
| F60-F69 | 203 (4.7%) | 69 (6.1%) | 60 (7.2%) | 9 (3.1%) | |
| F70-F79 | 22 (0.5%) | 13 (1.2%) | 9 (1.1%) | 4 (1.4%) | |
| F90-F99 | 87 (2%) | 7 (0.62%) | 7 (0.8%) | 0 (0%) | |
| Comorbidity | F0-F09 + F30-F39 | 15 (0.3%) | 11 (1%) | 8 (1%) | 3 (1.0%) |
| F10-F19 + F20-F29 | 23 (0.5%) | 23 (2%) | 11 (1.3%) | 12 (4.2%) | |
| F10-F19 + F30-F39 | 33 (0.8%) | 12 (1%) | 8 (1%) | 4 (1.4%) | |
| F10-F19 + F40-F49 | 36 (0.8%) | 5 (0.4%) | 5 (0.6%) | 0 (0%) | |
| F10-F19 + F60-F69 | 23 (0.5%) | 9 (0.8%) | 7 (0.8%) | 2 (0.7%) | |
| F20-F29 + F40-F49 | 13 (0.3%) | 12 (1%) | 10 (1.2%) | 2 (0.7%) | |
| F20-F29 + F60-F69 | 13 (0.3%) | 12 (1%) | 6 (0.7%) | 6 (2.1%) | |
| F30-F39 + F40-F49 | 47 (1.1%) | 8 (0.7%) | 6 (0.7%) | 2 (0.7%) | |
| F30-F39 + F50-F59 | 17 (0.4%) | 1 (0.1%) | 0 (0%) | 1 (0.3%) | |
| F30-F39 + F60-F69 | 83 (1.9%) | 32 (2.9%) | 22 (2.7%) | 10 (3.5%) | |
| F40-F49 + F40-F49 | 73 (1.7%) | 10 (0.9%) | 10 (1.2%) | 0 (0%) | |
| F40-F49 + F50-F59 | 32 (0.7%) | 1 (0.1%) | 1 (0.1%) | 0 (0%) | |
| F40-F49 + F60-F69 | 73 (1.7%) | 18 (1.6%) | 16 (1.9%) | 2 (0.7%) | |
| Other combinations | 224 (5.2%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| TOTAL | 4345 | 1116 (26%) | 829 (19%) | 287 (6.6%) | |